Document 0011
 DOCN  M95B0011
 TI    Immunologic adjuvants for modern vaccine formulations.
 DT    9511
 AU    Vogel FR; National Institute of Allergy and Infectious Diseases,
       Division; of AIDS, Bethesda, Maryland 20892, USA.
 SO    Ann N Y Acad Sci. 1995 May 31;754:153-60. Unique Identifier : AIDSLINE
       MED/95351597
 AB    Optimization of the immunogenicity of many new-generation vaccine
       formulations, including combination vaccines, will require the use of
       immunologic adjuvants other than the aluminum compounds in today's
       licensed vaccines. The selection of adjuvants for use in vaccine
       formulation may be as critical as the choice of the vaccine antigens
       themselves in providing optimal efficacy for the target populations,
       vaccine compliance, and cost. Adjuvants have diverse mechanisms of
       action and must be selected for use based on the immune responses
       desired for a particular candidate vaccine. Recent advances in the
       number and variety of adjuvants available for clinical evaluation
       coupled with the increased understanding of their mechanisms of action
       encourage the inclusion of adjuvants as part of rational vaccine design.
       Finally, the proposed standardized methods to evaluate adjuvant safety
       should be implemented for human candidate vaccines formulated with novel
       adjuvants.
 DE    *Adjuvants, Immunologic/HISTORY  Animal  AIDS Vaccines/*IMMUNOLOGY
       History of Medicine, 20th Cent.  Human  Macaca mulatta/IMMUNOLOGY
       Safety  SIV/IMMUNOLOGY  CLINICAL TRIAL  HISTORICAL ARTICLE  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).